- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01854749
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
February 22, 2016 updated by: Chang Jian Hua, Fudan University
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Cancer hospital Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Joined the study voluntarily and signed informed consent form;
Age 18-75
.Presence of at least one index lesion measurable by CT scan or MRI
- recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by pathology
- No radiotherapy, chemotherapy or other treatments prior to enrollment
- PS ECOG 0-1
- Life expectancy of more than 3 months
ANC≥2×109/L,PLT≥100×109/L,Hb≥90g/L
- Cr≤1.0×UNL
- TBIL≤1.25×UNL; ALT/AST≤2.5×UNL,with hepatic metastases ALT/AST≤5.0×UNL;AKP≤2.5×UNL
Exclusion Criteria:
there is radical cure of the cancer
- uncontrolled chronic diarrhea and esophageal obstruction
- Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases
- Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia
- Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix
- accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: S1 combined with cisplatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: from the first cycle of treatment (day one) to two month after the last cycle
|
from the first cycle of treatment (day one) to two month after the last cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
May 10, 2013
First Submitted That Met QC Criteria
May 13, 2013
First Posted (Estimate)
May 16, 2013
Study Record Updates
Last Update Posted (Estimate)
February 23, 2016
Last Update Submitted That Met QC Criteria
February 22, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Recurrence
- Esophageal Squamous Cell Carcinoma
- Antineoplastic Agents
- Cisplatin
Other Study ID Numbers
- S1- ESCC -CJH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
Fujian Medical University Union HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IVChina
-
The First Affiliated Hospital of Henan University...Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaboratorsActive, not recruitingStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage IIIChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell CarcinomaChina
Clinical Trials on S1 combined with cisplatin
-
Fudan UniversityCompletedCisplatin | Adenoid Cystic CarcinomasChina
-
Fudan UniversityRecruitingTriple-negative Breast CancerChina
-
University Medical Center GroningenNRG Oncology; Dutch Cancer SocietyRecruitingVulvar Cancer | Sentinel Lymph Node | Lymph Node MetastasesUnited States, Netherlands
-
National University Hospital, SingaporeRecruitingCancer | Liver DysfunctionSingapore
-
Mianyang Central HospitalUnknownEsophageal Squamous Cell Carcinoma
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Fudan UniversityUnknownEsophageal Squamous Cell CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
Fudan UniversityCompletedNon Small Cell Lung CancerChina
-
Hebei Medical University Fourth HospitalUnknownNon-small Cell Lung Cancer Stage ⅢA | Non-small Cell Lung Cancer Stage ⅡChina